Alfuzosin is a selective alpha-1 adrenergic receptor antagonist widely used in the management of benign prostatic hyperplasia (BPH), providing relief from lower urinary tract symptoms such as urinary frequency, urgency, nocturia, and weak urinary stream by relaxing smooth muscles in the prostate and bladder neck without significantly affecting systemic blood pressure. It is available in oral extended-release formulations, allowing once-daily dosing and improving patient adherence. Developed in the 1980s as part of efforts to create uroselective alpha-1 blockers that minimized the cardiovascular side effects associated with earlier non-selective alpha blockers, alfuzosin underwent extensive clinical evaluation, which demonstrated significant symptom improvement, enhanced urinary flow, and a favorable safety profile. Since its approval in the 1990s, alfuzosin has become a mainstay therapy in urology, offering effective management of BPH symptoms while maintaining cardiovascular safety, and continues to be widely prescribed for men with moderate to severe urinary obstruction due to prostatic enlargement.
